VivoSeq
Oncology

Bladder Carcinoma

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Bladder Carcinoma is an early-stage landscape with 0 programs across 1 company. The most active players are Anchiano Therapeutics Israel Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Anchiano Therapeutics Israel Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Unknown status5 · 38%
Completed3 · 23%
Terminated3 · 23%
Recruiting2 · 15%

Clinical Trials

Trial Activity

13 trials

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Recruiting·RRenJi Hospital·Phase 2·NCT06091124·22 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Recruiting·National Cancer Institute (NCI)·Preclinical·NCT06995898·24,000 enrolled
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Completed·AAnchiano Therapeutics Israel Ltd.·Phase 1·NCT01878188·38 enrolled
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Completed·YYale University·Phase 2·NCT00461851·17 enrolled
Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02736266·174 enrolled
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
Terminated·National Cancer Institute (NCI)·Phase 1·NCT00072137·21 enrolled
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
Terminated·UUniversity Hospital, Bordeaux·Phase 1·NCT01245660·3 enrolled
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
Terminated·UUniversity Hospital, Bordeaux·Phase 2·NCT03324282·65 enrolled
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04730219·48 enrolled
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04730232·63 enrolled
Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT05495724·176 enrolled
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT05418309·63 enrolled
A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma
Unknown status·TTianjin Medical University Second Hospital·Phase 4·NCT05220124·190 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)